EU-Wide OTC Approvals Highlight The Drawbacks Of National Processes
This article was originally published in The Tan Sheet
Executive Summary
National switches comprise the majority of OTC approvals in Europe, and likely will until the European Union opens restrictions on which drugs can use its nascent centralized switch process